<DOC>
	<DOCNO>NCT00298766</DOCNO>
	<brief_summary>This phase 1/2 open-label , dose-escalation study investigate single-agent therapy VELCADE patient previously treat systemic AL-amyloidosis require treatment .</brief_summary>
	<brief_title>Open-Label Phase 1/2 Study VELCADE Injection Patients With Light-chain ( AL ) -Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1 . Male Female 18 y/o old 2 . Female patient must practice effective method birth control 3 . Biopsyproven ALamyloidosis 4 . Must previously treat ( fail least 1 previous treatment ) opinion physician , patient require treatment 1 . Hypersensitivity boron mannitol 2 . Prior treatment VELCADE 3 . Patient require concomitant chemotherapy , radiotherapy ancillary therapy consider investigational 4 . Uncontrolled infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>